| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Roche Holding AG ADR | Solanezumab | Inherited Alzheimer's disease | Phase 2/3 | Intravenous | Genetic Disorder | |
| Roche Holding AG ADR | Evrysdi - (SUNFISH) | Spinal Muscular Atrophy (SMA) type 2 and 3 | Phase 2/3 | Oral | Genetic Disorder | |
| Roche Holding AG ADR | Evrysdi - (MANATEE) | Spinal Muscular Atrophy (SMA) in children | Phase 2/3 | oral | Genetic Disorder | |
| Roche Holding AG ADR | Evrysdi - (FIREFISH) | Spinal Muscular Atrophy (SMA) type 1 in infants | Phase 2/3 | Oral | Genetic Disorder | |
| Roche Holding AG ADR | Astegolima - (ALIENTO) | Chronic obstructive pulmonary disease (COPD) | Phase 2b | Data Released | Oral | Respiratory |
| Roche Holding AG ADR | RVT-3101 - (TUSCANY-2) | Ulcerative colitis | Phase 2b | Subcutaneous | Gastroenterology | |
| Roche Holding AG ADR | Pegozafermin - (ENLIVEN) | Nonalcoholic Steatohepatitis (NASH) | Phase 2b | Data Released | Subcutaneous | Gastroenterology |
| Roche Holding AG ADR | Vixarelimab (KPL-716) | Prurigo nodularis | Phase 2b | Ongoing | Subcutaneous | #N/A |